Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP1215887.RA-RmbFkgd-GAZyK6hui-CVXT2JNka2GAoIQHNIkv9APs130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP1215887.RA-RmbFkgd-GAZyK6hui-CVXT2JNka2GAoIQHNIkv9APs130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP1215887.RA-RmbFkgd-GAZyK6hui-CVXT2JNka2GAoIQHNIkv9APs130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP1215887.RA-RmbFkgd-GAZyK6hui-CVXT2JNka2GAoIQHNIkv9APs130_provenance.
- NP1215887.RA-RmbFkgd-GAZyK6hui-CVXT2JNka2GAoIQHNIkv9APs130_assertion description "[Despite the efficacy and superiority of EGFR TKIs over chemotherapy as first-line therapy, all patients will ultimately develop progressive disease, with a median of 9-13 months progression-free survival.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1215887.RA-RmbFkgd-GAZyK6hui-CVXT2JNka2GAoIQHNIkv9APs130_provenance.
- NP1215887.RA-RmbFkgd-GAZyK6hui-CVXT2JNka2GAoIQHNIkv9APs130_assertion evidence source_evidence_literature NP1215887.RA-RmbFkgd-GAZyK6hui-CVXT2JNka2GAoIQHNIkv9APs130_provenance.
- NP1215887.RA-RmbFkgd-GAZyK6hui-CVXT2JNka2GAoIQHNIkv9APs130_assertion SIO_000772 25176972 NP1215887.RA-RmbFkgd-GAZyK6hui-CVXT2JNka2GAoIQHNIkv9APs130_provenance.
- NP1215887.RA-RmbFkgd-GAZyK6hui-CVXT2JNka2GAoIQHNIkv9APs130_assertion wasDerivedFrom befree-2016 NP1215887.RA-RmbFkgd-GAZyK6hui-CVXT2JNka2GAoIQHNIkv9APs130_provenance.
- NP1215887.RA-RmbFkgd-GAZyK6hui-CVXT2JNka2GAoIQHNIkv9APs130_assertion wasGeneratedBy ECO_0000203 NP1215887.RA-RmbFkgd-GAZyK6hui-CVXT2JNka2GAoIQHNIkv9APs130_provenance.
- befree-2016 importedOn "2016-02-19" NP1215887.RA-RmbFkgd-GAZyK6hui-CVXT2JNka2GAoIQHNIkv9APs130_provenance.